| Name | Title | Contact Details |
|---|
PetDx® – The Liquid Biopsy Company for Pets™ is a molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health.
St. Mary`s Health Care System is a not-for-profit Catholic health care provider whose mission is to be a compassionate healing presence in the communities we serve. Founded in 1906 and sponsored by the Sisters of Mercy, St. Mary`s Health Care System is built on a foundation of values that include excellence, compassion, integrity and reverence for each person. St. Mary`s focuses on neurosciences, cardiac care, orthopedics, general medicine/general surgery, women`s and children`s health, and gastroenterology. The system includes 196-bed St. Mary`s Hospital in Athens and 25-bed St. Mary`s Good Samaritan Hospital in Greene County. Services include emergency care, intensive care, home health care/hospice services, inpatient and outpatient rehabilitation, assisted living, Alzheimer`s/dementia care, preventive care, state-of-the art diagnostic and therapeutic care and a growing network of physician practices. Named Georgia`s Hospital of the Year in 2006 and 2010, St. Mary`s is proud to be the official health care provider for the University of Georgia Athletic Association. St. Mary`s has earned the Joint Commission Gold Seal of Approval for advanced primary stroke care, advanced inpatient diabetes, heart failure care, knee replacement surgery and spine surgery.
PCS Medical Solutions is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wintersun Chemical LTD is a Ontario, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.